Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 412 across all filing types
Latest filing 2021-11-09 M&A Activity
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Due Diligence uber mogliche Integration von Geschaftstatigkeitsbereichen der Viromed Group voraussichtlich bis zur Hauptversammlung am 22. Dezember 2021 abgeschlossen
M&A Activity Classification · 99% confidence The document is a news release dated November 9, 2021, concerning NanoRepro AG. The primary subject is an update on the due diligence process for a potential integration of business areas from Viromed Group, with the expected completion tied to the upcoming Annual General Meeting (AGM) on December 22, 2021. The text mentions the AGM and that related documents will be available on the website. Since the document itself is an announcement about corporate activity (potential M&A/integration) and mentions the upcoming AGM where related information might be discussed, it is not a full report (like 10-K or IR). It is a general corporate news item. Given the options, this type of update, which is not explicitly an earnings release (ER), director dealing (DIRS), or capital change (CAP), fits best under the general regulatory announcement category, RNS, as it is distributed via DGAP (a common regulatory news service). However, the core topic is a potential Merger or Acquisition activity (integration of Viromed Group's business areas). The closest specific category related to M&A activity is 'TAR' (M&A Activity). Since this is an update on the due diligence phase of a potential transaction, TAR is the most appropriate classification, even though it's not the final deal announcement.
2021-11-09 German
NanoRepro AG: Nachfrage nach zuverlassigen SARS-CoV-2-Antigentests steigt weiter
Regulatory Filings Classification · 97% confidence The document is a short news release dated November 8, 2021, issued by NanoRepro AG via DGAP (a service for corporate news). It discusses rising demand for their SARS-CoV-2 tests following a report from the Paul-Ehrlich-Institut and announces their participation in the Medica trade fair. It is not a comprehensive financial report (like 10-K or IR), nor is it a formal earnings release (ER) detailing period results, nor a transcript (CT). It is a general market update and corporate announcement. Since it doesn't fit the specific categories like DIRS, DIV, CAP, or MANG, and it is a general news item distributed via a regulatory news service (DGAP), the most appropriate fallback category is Regulatory Filings (RNS), as it serves as a general corporate announcement not covered by more specific codes.
2021-11-08 German
NanoRepro AG und Viromed Medical GmbH unterzeichnen exklusive Vertriebsvereinbarung mit osterreichischem Partner
M&A Activity Classification · 99% confidence The document is a short news release dated October 21, 2021, announcing a specific business event: the signing of an exclusive distribution agreement between NanoRepro AG and Viromed Medical GmbH with an Austrian partner. It is tagged with 'DGAP-News' and uses keywords like 'Kooperation' (Cooperation) and 'Vertriebsvereinbarung' (Distribution Agreement). This is not a comprehensive financial report (like 10-K or IR), nor is it a standard earnings release (ER) which focuses on financial figures. It is a specific corporate action announcement. Since it doesn't fit perfectly into categories like M&A (TAR) or Capital Change (CAP), and it is a general corporate news item distributed via DGAP, the most appropriate general regulatory/news category is Regulatory Filings (RNS), which serves as a fallback for specific corporate announcements that aren't covered by other detailed codes. Given the short length and the nature of the announcement (a contract signing), RNS is the best fit among the provided options for a non-financial, non-management, non-voting corporate update.
2021-10-21 German
NanoRepro AG und Viromed bauen Partnerschaft aus und vermarkten gemeinsam neues Echtzeit-PCR-Analyseinstrument
Regulatory Filings Classification · 100% confidence The document is a press release dated September 28, 2021, announcing a business development: NanoRepro AG is expanding its partnership with Viromed to jointly market a new real-time PCR analysis instrument. It uses standard press release formatting, including the DGAP-News header, issuer responsibility statement, and contact information. This type of announcement, detailing a strategic business cooperation or product launch without being a formal financial report (like 10-K or IR) or a specific insider transaction, falls best under the general category for regulatory announcements or news releases that don't fit elsewhere. Since it is a corporate news item distributed via a service (DGAP), and it is not a formal financial filing, the most appropriate classification is Regulatory Filings (RNS), which serves as a general news/announcement fallback.
2021-09-28 German
Halbjahresabschluss 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALBJAHRESBERICHT 2021' (Half-Year Report 2021) for NanoRepro AG. It contains a 'ZWISCHENABSCHLUSS' (Interim Financial Statement) as of June 30, 2021, including a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), and notes (Anhang). Since it provides comprehensive financial data for a period shorter than a full fiscal year, it fits the definition of an Interim/Quarterly Report (IR). H2 2021
2021-09-28 German
NanoRepro AG: Exponentielles Wachstum im 1. Halbjahr 2021
Earnings Release Classification · 100% confidence The document is a news release dated September 23, 2021, titled "NanoRepro AG: Exponentielles Wachstum im 1. Halbjahr 2021" (Exponential Growth in the 1st Half of 2021). It explicitly reports key financial figures for the first half of the year (H1 2021), such as revenue (€120M) and EBITDA (€34.7M), compared to H1 2020. It also mentions that the full 'Halbjahresabschluss 2021' (Half-Year Financial Report) is published elsewhere. This structure—a brief announcement highlighting key performance indicators for a specific interim period (half-year)—is characteristic of an Earnings Release (ER). It is not the comprehensive Interim/Quarterly Report (IR) itself, but the initial announcement of the results. H1 2021
2021-09-23 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.